Apatinib mesylate tablet in the treatment of advanced malignant melanoma

• DOI: 10.2147/ott.s175507
• Publication Date: 2018-08-30T20:51:36Z
• Authors: Lingge Yang; Huiyan Zhu; Peng Luo; Shiqi Chen; Yu Xu; Chunmeng Wang
• Keywords: Apatinib; Mesylate; Clinical efficacy; Imatinib Mesylate

Background: Observing and studying clinical efficacy safety of apatinib mesylate tablet in the treatment advanced malignant melanoma (MM). Methods: Retrospectively analyzing data 22 patients with metastatic MM who had failed conventional chemotherapy from June 2016 to January 2018. All took 500 mg tablets per day. The should be evaluated according RECIST 1.1 criteria. Adverse events (AEs) graded NCI-CTCAE 4.0. Results: There were two cases partial remission (PR), 11 stable disease (SD) nine progressive (PD) MM, where objective rate (ORR) was 9.1% control (DCR) 59.1%. median progression-free survival (PFS) 7.5 months, 6-month (PFR) 54.7%. Six died overall (OS) not reached. AEs controllable all Grade 1–3. Conclusion: Apatinib have a certain curative effect on melanomas Stage IV chemotherapy. at daily dose are well tolerated by most patients. Keywords: apatinib, melanoma, targeted therapy, adverse reaction,